Gene polymorphisms in bladder cancer

被引:58
作者
Franekova, Maria [1 ]
Halasova, Erika [1 ]
Bukovska, Eva [1 ]
Luptak, Jan [2 ]
Dobrota, Dusan [3 ]
机构
[1] Comenius Univ, Dept Med Biol, Jessenius Fac Med, Martin 03754, Slovakia
[2] Comenius Univ, Jessenius Fac Med, Urol Clin, Martin 03659, Slovakia
[3] Comenius Univ, Dept Biochem, Jessenius Fac Med, Martin 03754, Slovakia
关键词
bladder cancer; polymorphisms;
D O I
10.1016/j.urolonc.2006.10.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In Europe, cancer of the bladder is the fourth most common cancer among men, accounting for 7% of total cancers. In the USA, bladder cancer is the fifth most common cancer in men and seventh in women. This disease is three times more common in men than in women. Several risk factors, such as cigarette smoking and occupational chemical exposure, contribute to bladder cancer development. The balance between activation and detoxification of carcinogens affects the amount of DNA damage that accumulates in cells. The entire process leading to DNA damage and subsequent repair of the damage involves a host of enzymes, many of which are polymorphic. Polymorphisms in metabolic enzyme genes and repair genes may cause alterations in protein product functions that can finally lead to genomic instability and carcinogenesis. In this article, we review the polymorphisms in a number of genes that have been found to be the modulators of bladder cancer risk. Improved understanding of the molecular biology of urothelial malignancies is helping to more clearly define the role of new prognostic indices and multidisciplinary treatment for this disease. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 104 条
[1]  
Abdel-Rahman SZ, 1998, CANCER DETECT PREV, V22, P129
[2]   Blocking oncogenic Ras signaling for cancer therapy [J].
Adjei, AA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1062-1074
[3]  
Aggarwal Bharat B., 2002, Current Drug Targets - Inflammation and Allergy, V1, P327, DOI 10.2174/1568010023344571
[4]   Glutathione S-transferase M1 gene polymorphism in bladder cancer patients: a marker for invasive bladder cancer? [J].
Aktas, D ;
Ozen, H ;
Atsu, N ;
Tekin, A ;
Sozen, S ;
Tuncbilek, E .
CANCER GENETICS AND CYTOGENETICS, 2001, 125 (01) :1-4
[5]   Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients [J].
Anwar, WA ;
AbdelRahman, SZ ;
ElZein, RA ;
Mostafa, HM ;
Au, WW .
CARCINOGENESIS, 1996, 17 (09) :1923-1929
[6]   A functional polymorphism in RGS6 modulates the risk of bladder cancer [J].
Berman, DM ;
Wang, YF ;
Liu, ZY ;
Dong, Q ;
Burke, LA ;
Liotta, LA ;
Fisher, R ;
Wu, XF .
CANCER RESEARCH, 2004, 64 (18) :6820-6826
[7]  
Biros E, 2000, NEOPLASMA, V47, P303
[8]   Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma:: a case-control study [J].
Blankenburg, S ;
König, IR ;
Moessner, R ;
Laspe, P ;
Thoms, KM ;
Krueger, U ;
Khan, SG ;
Westphal, G ;
Berking, C ;
Volkenandt, M ;
Reich, K ;
Neumann, C ;
Ziegler, A ;
Kraemer, KH ;
Emmert, S .
CARCINOGENESIS, 2005, 26 (06) :1085-1090
[9]   NQO1 T allele associated with decreased risk of later age at diagnosis lung cancer among never smokers:: results from a population-based study [J].
Bock, CH ;
Wenzlaff, AS ;
Cote, ML ;
Land, SJ ;
Schwartz, AG .
CARCINOGENESIS, 2005, 26 (02) :381-386
[10]  
Brockmoller J, 1996, CANCER RES, V56, P3915